Clinical Trial Update: Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab in combination with outpatient therapy for CD20+ non-Hodgkin lymphoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: Bayside Health | Conditions: Non-Hodgkin's Lymphoma (CD20+) | Phase 2 | Status: COMPLETED